Free Biopharma Daily Stock Updates - 07/29/21

$XBI $125.17 -1.66%

---

Want to access our searchable Catalyst Calendar of over 1,000 biotech stock events and more? Try BiopharmIQ for 30 days free, no credit card required. Check it out here!

---

Covid Updates

$INCY -0.8% FDA broadens existing emergency use of Lilly and Incyte's baricitinib in patients hospitalized with COVID-19 requiring oxygen. source

$COCP +9.1% Cocrystal Pharma’s SARS-CoV-2 3CL Protease Lead CDI-45205 Demonstrates Broad-Spectrum Activity Against the SARS-CoV-2 Delta and Gamma Variants. source

$TFFP +1.3% Augmenta Bioworks and TFF Pharmaceuticals Announce Positive In Vitro Data Demonstrating Binding and Neutralization of the SARS-CoV-2 Delta Variant by Lead Anti-COVID-19 Antibody, AUG-3387. source

$EBS +0.1% Emergent BioSolutions to Resume Manufacturing Covid-19 Vaccine at Bayview Facility. source

Pipeline Updates

$ERYP -3.0% ERYTECH Granted U.S. FDA Fast Track Designation for Eryaspase in Hypersensitive ALL. source

$ARDX -1.2% Ardelyx Receives Complete Response Letter from U.S. FDA for New Drug Application for Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis. source

$ALEC -21.1% Alector Presents 12-Month Results from the INFRONT-2 Phase 2 Open-label Clinical Study of AL001 for the Treatment of Symptomatic Frontotemporal Dementia Patients with a Progranulin Mutation. source

$CLSN +10.4% Results of Celsion’s OVATION 1 Study with GEN-1 in Patients with Advanced Ovarian Cancer Published in the Journal of Clinical Cancer Research. source

$SAVA -23.6% Cassava Sciences Announces Positive Cognition Data With Simufilam in Alzheimer’s Disease. source

$SAVA -23.6% Cassava Sciences Announces Positive Biomarker Data with Simufilam in Alzheimer’s Disease. source

$SCYX -0.3% SCYNEXIS Announces Two Oral Presentations on Pooled Data from the BREXAFEMME (Ibrexafungerp tablets) Phase 3 VANISH Program Demonstrating Consistent Efficacy in the Treatment for Vaginal Yeast Infections at the IDSOG 2021 Virtual Annual Meeting. source

$OCUL -3.9% Ocular Therapeutix™ Announces First Patient Dosed in U.S.-based Phase 1 Clinical Trial of OTX-TKI for the Treatment of Wet Age-Related Macular Degeneration. source

$DRNA 0.4% Dicerna Announces FDA Clearance of Investigational New Drug (IND) Application for DCR-AUD for the Treatment of Alcohol Use Disorder. source

$ACIU -3.5% AC Immune Presents Full Phase 1b Results on Anti-Abeta Vaccine and Discusses its First-in-Class Diagnostic for Parkinson’s Disease at AAIC 2021. source

$ARWR -0.1% Arrowhead Pharmaceuticals Receives Breakthrough Therapy Designation from U.S. FDA for ARO-AAT for the Treatment of Alpha-1 Antitrypsin Deficiency Associated Liver Disease. source

$PCRX +0.1% New Analysis Shows iovera° Plays a Critical Role in Achieving Significant Reductions in Opioid Use, Pain Scores, and Hospital Stay Following Total Knee Arthroplasty. source

$PROG -9.8% Progenity Announces Successful Completion of Clinical Validation Study and Achievement of the Primary Endpoint for its Preeclampsia Rule-Out Test. source

$IONS -2.8% Ionis completes enrollment in pivotal NEURO-TTRansform study of eplontersen. source

$BCEL -40.2% Atreca Presents Initial Clinical Data from Phase 1b Trial of ATRC-101 in Select Advanced Solid Tumors. source

$AVXL -14.4% Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Significantly Prevented Aβ (Abeta)-induced Cognitive Deficits with Confirmed Significant Biomarker-response in Animal Model of Alzheimer’s Disease. source

$SIGA +1.4% SIGA Announces Collaboration with Oxford University to Support Expanded Access Protocol for Use of TPOXX® (Tecovirimat) To Treat Monkeypox in Central African Republic. source

$ANVS -60.3% Annovis Bio Presents New Clinical and Biomarker Data at 2021 Alzheimer's Association International Conference. source

Financial Updates

$IMAB +3.2% I-Mab Announces Authorization of a Renewed Stock Repurchase Program by the Company up to US$40 Million. source

---

Posted by FS